mRNA |
YM-155 |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
2e-08 |
mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
0.27 |
3e-07 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.19 |
3e-07 |
mRNA |
CAL-101 |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
3e-07 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
5e-07 |
mRNA |
temsirolimus |
GDSC1000 |
pan-cancer |
AAC |
0.17 |
6e-07 |
mRNA |
Rapamycin |
gCSI |
pan-cancer |
AAC |
0.27 |
1e-06 |
mRNA |
selumetinib:tretinoin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
2e-06 |
mRNA |
NSC632839 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
3e-06 |
mRNA |
TW 37 |
GDSC1000 |
pan-cancer |
AAC |
0.15 |
8e-06 |